New drug CAY001 enters first human safety trial
NCT ID NCT06845839
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests the safety of a new drug called CAY001 in 24 healthy adults aged 18-50. Participants receive a single dose of the drug or a placebo by IV, and researchers monitor them for 28 days for side effects and how the drug moves through the body. The goal is simply to see if it is safe enough to study further.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CAY001 (a complex of polyphosphate and silica nanoparticles)
What could go wrong
This is a very early, first-in-human study with only 24 healthy people. It is designed to check safety, not to treat any disease, so it may not lead to any medical use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
TKL Research
RECRUITINGFair Lawn, New Jersey, 07410, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••